Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term follow-up of BPX-501 (rivogenlecleucel) in pediatric patients
NCT03733249Phase 2Terminated
- Sponsor
- Bellicum Pharmaceuticals, Inc.
- Start
- Jan 2017
- Primary completion
- Jun 2020
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of rivogenlecleucel in acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL), myelodysplastic syndrome (MDS), primary immunodeficiency (PI), sponsored by Bellicum Pharmaceuticals, Inc.. Started Jan 2017; status: terminated.
02
Drugs
rivogenlecleucel
03
Conditions
acute lymphoblastic leukemia (ALL)acute myeloid leukemia (AML)non-Hodgkin lymphoma (NHL)myelodysplastic syndrome (MDS)primary immunodeficiency (PI)
Beyond the preview
Go deeper on NCT03733249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03733249.